Research programme: anti-inflammatory kinase inhibitors - Arrien Pharmaceuticals
Alternative Names: ARN-4026; ARN-4079; ATP-competitive kinase inhibitors - Arrien Pharmaceuticals; JAK3 inhibitors - Arrien Pharmaceuticals; JAK3/ITK inhibitors - Arrien PharmaceuticalsLatest Information Update: 28 Dec 2019
At a glance
- Originator Arrien Pharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Psoriasis in USA (PO)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (PO)
- 12 Sep 2016 Preclinical development is ongoing for Rheumatoid arthritis (Arrien Pharmaceuticals Pipeline, September 2016)